Skip to content

Visual Biofeedback Through Transperineal Ultrasound During the Expulsive Phase of Labour to Improve Maternal Childbirth Satisfaction

Visual Biofeedback (VB) Through Trans-Perineal Ultrasound (TPU) During the Active 2nd Stage of Labour to Improve Maternal Childbirth Satisfaction: a Randomised Controlled Trial

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06847308
Acronym
RCT:VB-TPU
Enrollment
488
Registered
2025-02-26
Start date
2025-03-01
Completion date
2028-02-28
Last updated
2025-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Childbirth, Labor and Delivery, Labor Stage, Second, Satisfaction With Care

Keywords

2nd stage of labour, visual biofeedback, maternal childbirth satisfaction, obstetrics, ultrasound, trans-perineal ultrasound

Brief summary

Childbirth is generally regarded as a positive life-changing experience. Up to 44% of women may however experience this as a traumatic event, with 3% suffering from post-traumatic stress disorder after childbirth. The aetiology of a traumatic childbirth experience is a complex interplay between pre-birth, intra-partum and postnatal factors. Feelings of loss of control, lack of interaction with the obstetric caregiver and lack of emotional or practical support during labour are important contributing factors. This trial aims to investigate the effect of providing Visual Biofeedback (VB) through Trans-Perineal Ultrasound (TPU) during the active 2nd stage of labour on maternal childbirth satisfaction. The hypothesis is that the intervention will improve patient-caregiver communication and enhance parturient women's sense of control and empowerment, ultimately improving the birth experience.

Interventions

BEHAVIORALvisual biofeedback through trans-perineal ultrasound

Trans-perineal ultrasound will be used to provide visual biofeedback during the active 2nd stage of labour, this for ten consecutive uterine contractions / pushing efforts

Sponsors

Universitaire Ziekenhuizen KU Leuven
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)

Masking description

Trial statistician

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

(all must be met): 1. Voluntary written informed consent of the participant. 2. Term (37-42w) singleton gestations. 3. Vaginally nulliparous (no previous vaginal birth \> 20 weeks of gestation). 4. Fetus in cephalic presentation, without any major congenital or chromosomal anomalies. 5. Admitted to the delivery unit in labour, regardless of the onset (spontaneous or induced). 6. Epidural analgesia in situ. 7. Non-pathological CTG at the time of recruitment (2015 FIGO classification).

Exclusion criteria

(if one or more is present): * Significant psychiatric comorbidity (psychiatric follow-up during pregnancy, or active (psycho-pharmacological) treatment). * History of severe PFDs/surgery (or any other condition affecting pelvic floor function/anatomy, besides pregnancy and delivery). * Significant neurological disease e.g., spinal injury, multiple sclerosis, diabetic neuropathy, etc. * Significant connective tissue disorders (e.g., Ehlers-Danlos syndrome). * Severe active maternal (pregnancy-related) comorbidity: non-exhaustive e.g., severe hypertensive disorder, significant antepartum haemorrhage, sepsis, thromboembolism, severe pre-existing cardiac/respiratory/neurological disease, etc. Well-controlled comorbidities will not be considered

Design outcomes

Primary

MeasureTime frameDescription
Maternal childbirth satisfactionFrom enrollment to two days after deliveryMaternal childbirth satisfaction will be assessed using the Birth Satisfaction Scale revised (BSS-R) questionnaire. The total score ranges from 0/40 to 40/40, with lower scores indicating worser satisfaction.
Vaginal birth-induced perineal traumaAssessment immediately after childbirth (delivery of the baby)Assessed immediately after delivery through clinical examination (inspection and palpation) of the perineal region and grading of any injury according to the Sultan classification (intact - firs degree tear: vaginal mucosa/perineal skin - second degree tear: perineal muscles - third degree tear: external and/or internal anal sphincter - fourth degree tear: anorectal mucosa).

Secondary

MeasureTime frameDescription
Anal incontinenceFrom enrollment to the end of follow-up at 1 year postpartumThe presence and severity of anal incontinence will be assessed twice: once around 12 weeks postpartum, and once additionally 6-12 months postpartum. The incidence and severity of anal incontinence will be self-reported, using the standardized and validated St. Marks Incontinence Score. Total scores range from 0/24-24/24, with higher scores indicating worser symptoms.
Prolapse symptomsFrom enrollment to the end of follow-up at 1 year postpartumThe presence and severity of prolapse symptoms will be assessed twice: once around 12 weeks postpartum, and once additionally 6-12 months postpartum. The incidence and severity of prolapse symptoms will be self-reported, using the standardized and validated Pelvic Organ Prolapse Distress Index for symptoms of pelvic organ prolapse. Total scores range from 0/24-24/24, with higher scores indicating worser symptoms.
Sexual functionFrom enrollment to the end of follow-up at 1 year postpartumSexual function will be assessed twice: once around 12 weeks postpartum, and once additionally 6-12 months postpartum. Sexual function will be self-reported, using the standardized and validated Female Sexual Function Index (19 items, range 2/36-36/36). Higher scores indicate more severe dysfunction.
Delivery modeFrom enrollment to the end of the deliverySpontaneous vaginal vs. operative delivery (vacuum and/or forceps delivery or 2nd stage caesarean section).
Duration of the active total second stageFrom the onset of active maternal pushing efforts (= onset of the active second stage) and childbirth (= delivery of the baby), estimated to range between 0-120 minutes.The period between the onset of active maternal pushing efforts (= active second stage) and delivery of the baby.
Delta-AoPDuring the active second stage of labour, from the first to the 10th consecutive pushing effort, estimated interval 20 minutes (4-5 contractions/10 minutes).Differences in the angle of progression (AoP, in degrees) at rest and maximal Valsalva during the active 2nd stage (i.e., active maternal pushing efforts), measured by transperineal ultrasound during the first and 10th consecutive pushing effort.
Delta LAMDuring the active second stage of labour, from the first to the 10th consecutive pushing effort, estimated interval 20 minutes (4-5 contractions/10 minutes).Differences in the anteroposterior diameter of the puborectalis part of the levator ani muscle (LAM) at rest and maximal Valsalva during the active 2nd stage (= active maternal pushing efforts), measured by transperineal ultrasound during the first and 10th consecutive pushing effort.
Duration of the total second stageFrom the onset of full cervical dilatation (= onset of the second stage) until childbirth (= delivery of the baby), estimated to range between 0-180 minutes.The period between full cervical dilatation and delivery of the baby.
Urinary incontinenceFrom enrollment to the end of follow-up at 1 year postpartumThe presence and severity of urinary incontinence will be assessed twice: once around 12 weeks postpartum, and once additionally 6-12 months postpartum. The incidence and severity of urinary incontinence will be self-reported, using the standardized and validated International Consultation on Incontinence Questionnaire - Short Form questionnaire for urinary incontinence. Total scores range from 0/21-21/21, with higher scores indicating worser symptoms.

Countries

Belgium

Contacts

Primary ContactBram Packet, MD
bram.packet@kuleuven.be+3216348824
Backup ContactKobe Haenen, MD
kobe.haenen@kuleuven.be+3216348824

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026